Index

Volume 15, 2002

Subject Index

Acetylcholinesterase inhibitors, 228
Activities of Daily Living, 12–15, 50–53
A53T mutation, 218–219
Agitation, 95–98, 171–174
Alcohol, 31–36
Alpha-1-antichymotrypsin, 24–29
Alpha-synucleinopathy, 195–199, 218–219
Alzheimer's disease, 20–29, 38–42, 55–72, 82–89, 95–117, 156–174, 182–192, 210–214, 224–237
Antichymotrypsin, 12–15
Antipsychotics, 156–166, 228–229
Anxiety disorder, 151
Apolipoprotein E, 20–23, 24–29, 205
Ataxia, 7–10
Atrophy, 82–89, 195–199
Attention, 99–109

Babcock Story Recall Test, 99–109
Behavior, 95–98, 110–117
Behavioral Rating Scale for Dementia, 110–117
Bipolar disorder, 128–132
Blue rubber bleb nevus syndrome, 7–10
Brain, 203–204, 218, 220

Capgras' syndrome, 239–241
Caregivers, 16–19, 68–72
Cerebral cortex, 203
Cerebral glucose, 200–203
Cholinesterase inhibitors, 227–228
Chromosome 4p, 219
Circadian rest-activity cycle, 55–59
Clock Drawing test, 12–15
Clozapine, 157–158, 161–162
Cognitive function, 12–15, 31–36, 110–117, 161–164, 166, 175–179, 189, 225, 233–237
Contursi kindred, 218–219
Cortex, 202–203
Creatinine, 77–81

Decision making, 68–72
Delusions, 190, 239–241
Dementia, 7–10, 16–19, 50–59, 110–117, 156–166, 171–174, 181–230, 239–241
Dementia with Lewy bodies, 156–166, 181–230, 239–241
Depression, 20–23, 38–42, 44–48, 134–138, 141–153
Diagnostic and Statistical Manual of Mental Disorders, 44–48, 188–192
Digit Cancellation Test, 99–109
Dopaminergic agents, 229
Double vision, 239–241

Electroconvulsive therapy, 73–75
Encephalopathy, 175–179
Eye movement, 195–199

Familial Lewy body diseases, 217–222
Folstein Mini-Mental Status Examination, 31–36
Functional changes, 110–117

Global Deterioration Scale, 50–53
Glucose, 200–203
Golbe kindred, 221

Hallucinations, 189, 203, 225, 239–241
Hamilton Depression Rating Scale, 20–23, 38–42
Hashimoto's encephalopathy, 175–179
Health Care Financing Administration, 91–94
Health care services, 1–6, 121–126, 128–132, 134–138
Hippocampal atrophy, 82–89
Hopelessness, 38–42
Hydroxyrisperidone, 77–81
Hypometabolism, 201–202

Idiopathic rapid eye movement, 195–199
Instrumental Activities of Daily Living, 12–15
Intermarried families, 219
International Classification of Disease, 188–192
Iowa kindred, 219
Ishikawa kindred, 219

Lewy bodies, 156–166, 181–230, 239–241
Longitudinal research, 1–6

Magnetic resonance imaging, 7–10, 204–205
Manic syndromes, 128–132
Melancholia, 44–48
Memory transfer, 82–89
Mental health services, 1–6, 121–126, 128–132, 134–138
Metabolism, 200–206
Mini-Mental State Examination, 12–15, 99–109, 171–174, 233–237
Mood disorders, 190
Morphology, 204–205
Motor function, 225
Multiple systems atrophy, 195–199

Neurochemistry, 203–204
Neurodegenerative diseases, 217–222
Neuroimaging, 83–84, 200–206
Neuroleptic sensitivity, 190
Neuropathology, 210–214
Neuropsychiatric Inventory, 171–174
9-hydroxyrisperidone, 77–81
Nursing homes, 141–146

Occipital cortex, 202–203
Occipital hypometabolism, 201–202
Ohara kindred, 219–221
Olanzapine, 159–160, 163

PARK1 gene, 218–219
PARK4 gene, 219
Parkinsonian motor signs, 225
Parkinsonism, 189–190, 217–222, 225
Parkinson's disease, 61–65, 156–166, 182–201, 210–230
Pharmacologic treatment, 141–146, 224–230
Positron emission tomography, 204
Poststroke depression, 38–42
Psychogeriatric inpatient unit, 91–94
Psychopathology, 110–117
Psychosis, 24–29
Psychotropics, 95–98

Quetiapine, 160–161, 163–164

Race, 151–152
Rapid eye movement, 195–199
Restraints, 91–94
Risperidone, 77–81, 158–159, 162–163
Rural aged, 1–6

Schizophrenia, 121–126
Seclusion, 91–94
Single photon emission computed tomography, 204
Sleep, 61–65, 195–199
Stroke, 38–42, 61–65
Subcortical stroke, 61–65
Suicide, 38–42
Symbol Cancellation Test, 99–109
Synucleinopathy, 197, 217–222

Taiwanese caregivers, 16–19
Temporal lobe, 204
Time and Change test, 12–15
Transfer, 82–89

Vascular dementia, 50–53, 156–166
Visual hallucinations, 203, 225, 239–241

Wakabayashi kindred, 219